Use of Hormonal Therapy in Men With Metastatic Prostate Cancer
2006; Lippincott Williams & Wilkins; Volume: 176; Issue: 2 Linguagem: Inglês
10.1016/j.juro.2006.03.098
ISSN1527-3792
AutoresGrace L. Lu‐Yao, Dirk F. Moore, John Oleynick, Robert S. DiPaola, Siu‐Long Yao,
Tópico(s)Hormonal and reproductive studies
ResumoNo AccessJournal of UrologyAdult urology1 Aug 2006Use of Hormonal Therapy in Men With Metastatic Prostate Cancer Grace Lu-Yao, Dirk F. Moore, John Oleynick, Robert S. DiPaola, and Siu-Long Yao Grace Lu-YaoGrace Lu-Yao Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, New Brunswick, New Jersey Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey , Dirk F. MooreDirk F. Moore Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Department of Biostatistics, School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway and Dean, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey , John OleynickJohn Oleynick Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Department of Biostatistics, School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway and Dean, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey , Robert S. DiPaolaRobert S. DiPaola Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey , and Siu-Long YaoSiu-Long Yao Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey View All Author Informationhttps://doi.org/10.1016/j.juro.2006.03.098AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Bilateral orchiectomy or luteinizing hormone releasing hormone agonists represent the standard of care for metastatic prostate cancer. In this population based study we assessed the use rates of these therapies in men who died of prostate cancer. Material and Methods: A total of 9,110 men 65 years or older who died of prostate cancer in 1991 to 2000 were identified through the population based Surveillance, Epidemiology and End Results, and Medicare linked database to determine hormonal therapy use rates. A modified Poisson regression model was used to estimate the adjusted effects of various factors associated with hormone use. Results: Approximately 38% of black and 25% of white men did not receive hormonal therapy before dying of prostate cancer. After adjusting for cancer status at diagnosis and other potential confounding factors black race and residence in low income areas were associated with lower hormonal therapy use (relative risk 0.73, 95% CI 0.67 to 0.80 and 0.91, 95% CI 0.85 to 0.98, respectively). Hormonal therapy use was most comprehensive in the Northeast. Conclusions: A substantial number of men who die as a consequence of prostate cancer never receive hormonal therapy. The use of hormonal therapy varies significantly. Further studies are warranted to determine factors that may be associated with the incomplete use of hormonal therapy for metastatic prostate cancer. References 1 : American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol2004; 22: 2927. Google Scholar 2 : Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol1997; 79: 235. Google Scholar 3 : A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol2001; 166: 508. Link, Google Scholar 4 : Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care2002; 40: IV. Google Scholar 5 : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med2005; 352: 154. Google Scholar 6 : Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst1999; 91: 1719. Google Scholar 7 : Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol1992; 45: 613. Google Scholar 8 : A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol2004; 159: 702. Google Scholar 9 The State of Health Care Quality. Washington, D. C: National Committee for Quality Assurance2003: 60. Google Scholar 10 : How rapidly do oncologists respond to clinical trial data?. Oncologist2005; 10: 15. Google Scholar 11 : Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol1996; 14: 2250. Google Scholar 12 : Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol1996; 30: 93. Google Scholar 13 : A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ2003; 327: 195. Google Scholar 14 : Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med1996; 335: 791. Google Scholar 15 : Medicare coverage, supplemental insurance, and the use of mammography by older women. N Engl J Med1995; 332: 1138. Google Scholar 16 : Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology1986; 27: 21. Google Scholar 17 : Cancer: Principles and Practice of Oncology. Philadelphia: J. B. Lippincott1997. Google Scholar 18 : A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol2000; 163: 519. Link, Google Scholar 19 : Determining cause of death in prostate cancer: are death certificates valid?. J Natl Cancer Inst2001; 93: 1822. Google Scholar 20 : Shattuck lecture: clinical research to clinical practice—lost in translation?. N Engl J Med2003; 349: 868. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byLu-Yao G, Moore D, Oleynick J, DiPaola R and Yao S (2018) Population Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate CancerJournal of Urology, VOL. 177, NO. 2, (535-539), Online publication date: 1-Feb-2007. Volume 176Issue 2August 2006Page: 526-531 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsMedicareSEER programhormonalprostatic neoplasmsprostateantineoplastic agentsAcknowledgmentsThe Applied Research Branch, Division of Cancer Prevention and Population Science, National Cancer Institute, Office of Information Services and Office of Strategic Planning, Health Insurance Portability and Accountability Act Compliance Federation of America, Information Management Services, Inc., and SEER Program tumor registries assisted with the creation of the SEER-Medicare database. Judith Manola reviewed the manuscript.MetricsAuthor Information Grace Lu-Yao Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, New Brunswick, New Jersey Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey More articles by this author Dirk F. Moore Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Department of Biostatistics, School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway and Dean, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey More articles by this author John Oleynick Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Department of Biostatistics, School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway and Dean, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey More articles by this author Robert S. DiPaola Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey Financial interest and/or other relationship with Aventis, Sanofi, Novartis, Abbott, BUS, Therion, Dendreon, Schering and Cellgurency. More articles by this author Siu-Long Yao Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey Financial interest and/or other relationship with Schering-Plough. More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)